Patient P-02628

Synthetic patientMETA-24 · Day 174 · 45–54 · F · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 69 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 71 SC-12 recommended — Supportive Compound SC-12
Day 72 Patient accepted — Started SC-12 in the companion
Day 78 GI symptom burden −18% vs expected — Supportive Compound SC-12
Day 84 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 69.

Primary contributors, last 14 days

GI instability+6
Inflammatory activity+2

What helped?

Supportive Compound SC-12Day 71
Result: symptom burden −18%

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
89% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 58
- WearableHRV 35 ms, trending down
Autonomic recovery ↓65
- WearableResting HR 73 bpm
- Wearable955 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 63 and rising
- WearableSleep 5.6 h, below personal baseline
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 39/100
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑20
- BloodToxicity index 44

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.2 · butyrate capacity 39/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiNormal
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 37 ms
Sleep: 5.8 h
Steps: 680
Resting HR: 74 bpm

Daily log: GI score 63, nutritional resilience 41, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02348	56%	S14	GI-04	improved	49
P-02535	56%	S14	SC-12	improved	50
P-02320	55%	S14	NP-02	improved	50
P-02516	55%	S14	SC-12	improved	51
P-02574	55%	S14	ME-01	improved	45
P-02657	54%	S14	—	—	42
P-02014	52%	S14	GI-04	improved	48
P-02316	51%	S14	GI-04	improved	51
P-02057	50%	S14	GI-04	improved	47
P-02253	50%	S14	NP-02	no change	41
P-02670	50%	S14	SC-12	improved	45
P-02059	49%	S03	SC-12	improved	41